Evidence map›Paper›PMID 30691124›Full record

ArticleInternational journal of molecular sciences2019

Kidney Injury by Variants in the

Jenny Frese, Matthias Kettwig, Hildegard Zappel, Johannes Hofer, Hermann-Josef Gröne, Mato Nagel, Gere Sunder-Plassmann, Renate Kain, Jörg Neuweiler, Oliver Gross

Registry-linked trialOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02378805 (European Alport Therapy Registry - European Initiative Towards Delaying Renal Failure in Alport Syndrome), which is not on this map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.8field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02378805 recruitingnot on this map

European Alport Therapy Registry - European Initiative Towards Delaying Renal Failure in Alport Syndrome: Current and Novel Therapies

Typeobservational_patient_registrySponsorUniversity Hospital GoettingenRan1995 to 2036Enrolled800ConditionsAlport Syndrome, Hereditary Kidney Disease, Pediatric Kidney Disease, Thin Basement Membrane DiseaseArmsACE-inhibitor, Angiotensin-receptor blocker (ARB), HMG-Coenzyme inhibitor (statin), Spironolactone or Finerenone, Paricalcitol
3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. A pedigree withAmerican journal of translational research · 2022
    Article
  7. Review
  8. Article
  9. Kidney Inflammation, Injury and Regeneration.International journal of molecular sciences · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 3 countries.

Jenny FreseClinic of Nephrology and Rheumatology, University Medical Center Goettingen, 37075 Goettingen, Germany. jenny.frese@dpdhl.com.
Matthias KettwigClinic of Pediatrics and Adolescent Medicine, University Medical Center Goettingen, 37075 Goettingen, Germany. matthias.kettwig@med.uni-goettingen.de.ORCID 0000-0003-4804-7716
Hildegard ZappelClinic of Pediatrics and Adolescent Medicine, University Medical Center Goettingen, 37075 Goettingen, Germany. hzappel@med.uni-goettingen.de.
Johannes HoferDepartment of Pediatrics, Pediatrics I, Innsbruck Medical University, 6020 Innsbruck, Austria. Johannes.Hofer@i-med.ac.at.
Hermann-Josef GröneDepartment of Cellular and Molecular Pathology, German Cancer Research Center, 69120 Heidelberg, Germany. h.-j.groene@dkfz-heidelberg.de.
Mato NagelCenter for Nephrology and Metabolic Disorders, Molecular Diagnostics, 02943 Weißwasser, Germany. nagel@moldiag.de.
Gere Sunder-PlassmannDivision of Nephrology and Dialysis, Department of Medicine III, Medical University of Vienna, 1090 Vienna, Austria. Gere.Sunder-Plassmann@meduniwien.ac.at.ORCID 0000-0002-9253-9921
Renate KainDepartment of Pathology, Medical University of Vienna, 1090 Vienna, Austria. renate.kain@meduniwien.ac.at.ORCID 0000-0002-2428-543X
Jörg NeuweilerInstitute of Pathology, Kantonsspital, 9007 St. Gallen, Switzerland. joerg.neuweiler@kssg.ch.
Oliver GrossClinic of Nephrology and Rheumatology, University Medical Center Goettingen, 37075 Goettingen, Germany. gross.oliver@med.uni-goettingen.de.ORCID 0000-0002-8390-8852
Medical University of Vienna · ATGerman Cancer Research Center · DEInnsbruck Medical University · ATKantonsspital St. Gallen · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Kidney injury due to focal segmental glomerulosclerosis (FSGS) is the most common primary glomerular disorder causing end-stage renal disease. Homozygous mutations in either glomerular basement membrane or slit diaphragm genes cause early renal failure. Heterozygous carriers develop renal symptoms late, if at all. In contrast to mutations in slit diaphragm genes, hetero- or hemizygous mutations in the X-chromosomal

Indexed as

Polymorphism, Single NucleotideAcute Kidney InjuryAdultChildChild, PreschoolCollagen Type IVFemaleGenetic Predisposition to DiseaseGlomerulosclerosis, Focal SegmentalHemizygoteHeterozygoteHumansInfantIntracellular Signaling Peptides and ProteinsMaleMembrane ProteinsCOL4A5 protein, humanCollagen Type IVIntracellular Signaling Peptides and ProteinsMembrane ProteinsnephrinNPHS2 proteinalport syndromefocal segmental glomerulosclerosisglomerular basement membranekidney injurymodifier genenephrinpodocinslit diaphragm

Identifiers

PMID30691124
PMCPMC6386959
OpenAlexW2911347262

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.